FIELD: pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics. Described is a stable pharmaceutical composition for oral consumption contains lamivudine in amount of 10 mg/ml, free of ethanol and parabens. Composition contains a hydrophilic carrier composed of water, preserving agent, complexing agent and process additives. Preserving agent is cetylpyridinium chloride in amount from 0.1 mg/ml to 0.2 mg/ml. Complexing agent is disodium edetate in amount from 0.11 mg/ml to 0.2 mg/ml. Correctives of taste, colour, odour and pH regulators are used as process additives, wherein the formulation has pH from 5.5 to 7.0.
EFFECT: invention provides implementation of the above application, as well as wider range of drugs.
1 cl, 1 dwg, 9 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
STABLE SOFT DOSAGE FORM OF DIOXIDINE | 2020 |
|
RU2741787C1 |
PHARMACEUTICAL KETOROLAC-BASED COMPOSITION IN FORM OF NASAL SPRAY AND METHOD FOR PREPARATION THEREOF | 2015 |
|
RU2611659C1 |
MEDICATION FOR TREATING DERMATOSIS (VERSIONS) | 2013 |
|
RU2548764C2 |
LIQUID MEDICINAL FORM RISPERIDONE AND METHOD FOR ITS MANUFACTURE | 2016 |
|
RU2646812C1 |
PHLEBOTROPHIC COMBINATION PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2704976C2 |
ALPHA-INTERFERON COMPOSITION AS AQUEOUS SOLUTION | 2000 |
|
RU2232595C2 |
DIFLUPREDNATE EMULSION COMPOSITION CONTAINING ANTIMICROBIAL METAL | 2014 |
|
RU2666961C2 |
PHAMACEUTICAL FORMULATION OF ANTI-INFLAMMATORY AND ANTIBACTERIAL ACTION IN OINTMENT FORM WITH HYDROPHOBIC BASE APPLIED FOR DERMATOSES TREATMENT (VERSIONS) | 2006 |
|
RU2325912C1 |
DIFLUPREDNATE EMULSION COMPOSITION CONTAINING ZINC | 2014 |
|
RU2675813C2 |
COMBINED SOFT DOSAGE FORM OF DIOSMIN AND TROXERUTIN | 2018 |
|
RU2689409C1 |
Authors
Dates
2016-06-20—Published
2015-01-19—Filed